Curis Lifesciences Reports 22% YoY Revenue Growth and 53% Sequential PAT Growth in H1 FY27; Expands Injectables Portfolio and Enters Nigeria
Nov 16, 2026
Ahmedabad (Gujarat) [India], November 16: Curis Lifesciences Limited today announced its unaudited financial results for the half-year ended 30th September 2026 (H1 FY27).
Read More...